Dyadic’s (DYAI) enterprise value appreciated 10x from $10M to $110M in one year for no fundamental reason.
DYAI has tried and failed to make a pharmaceutical commercial agreement with its C1 platform for 16 years, and we doubt it ever will.
Over the past year, DYAI has been highly promotional, attending many conferences, publishing PRs and paying different stock analysts/promoters.
The CEO has a questionable past, and was previously fired from DYAI following a scandal.
In DYAI’s recent PR regarding the coronavirus,its collaborative partner failed to mention working with DYAI or its platform.
See the full report on Seeking Alpha here.